Stool Samples DNA Extraction : Parkinson’s Disease by Gashi, Albina
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Albina Gashi 
 
Stool Samples DNA Extraction 
 
Parkinson’s Disease 
Helsinki Metropolia University of Applied Sciences 
Bachelor of Sciences 
Laboratory Sciences 
Thesis 
18.12.2017 
 
  
 
 
Author(s) 
Title 
 
Number of Pages 
Date 
Albina Gashi 
Stool Samples DNA Extraction 
 
25 pages + 36 appendices  
18 December 2017  
Degree Bachelor of Laboratory Sciences 
Degree Programme Laboratory Sciences 
Instructor(s) 
 
Petri Auvinen, Research Director 
Lars Paulin, Laboratory Engineer  
Pedro Pereira, Researcher 
Tiina Soininen Senior Lecturer  
The subject of the study was DNA isolation from stool samples in persons who are at 
risk to get Parkinson’s disease. The study was conducted at the University of Helsinki, 
Institute for Biotechnology at the DNA sequencing and genomics laboratory. This thesis 
is one part of the University of Helsinki Parkinson's disease study. The focus of this study 
was to isolate DNA from stool samples and to create a summary of the results of the 
data.  
 
The University of Helsinki has collected 745 stool samples. The purpose was to random-
ize the stool samples first and then isolate the DNA. Isolated DNA samples were meas-
ured with a NanoDrop spectrophotometer apparatus to find out the DNA concentration 
of the samples. The theoretical part of the thesis includes information on Parkinson's 
disease and material handling. Based on an established protocol, DNA isolation was 
performed.  
 
For the study, 745 pieces of stool samples were collected. The 745 stool samples were 
randomly divided into batches of 23 samples for DNA isolation. To each batch one blank 
for kit contamination control was added, for a total of 24 samples per isolation batch.  
 
Based on the NanoDrop spectrophotometer result, the lowest result was 0.61 ng/L and 
information will be the highest result was 26.6 g/L. Isolated DNA samples studies will 
continue by using PCR amplification, and will be samples sequenced, processed bioin-
formatically, and analyzed with statistical methods.  
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Opinnäytetyön aiheena oli DNA:n eristäminen ulostenäytteistä henkilöiltä, joilla on riski 
sairastua Parkinsonin tautiin. Opinnäytetyö tehtiin Helsingin yliopiston biotekniikan ins-
tituutissa DNA-sekvensointi- ja genomiikkalaboratoriossa. Tämä opinnäytetyö on osana 
Helsingin yliopiston Parkinsonin taudin tutkimusta. Opinnäytetyön prioriteetti oli DNA:n 
eristäminen ulostenäytteistä ja yhteenvedon tekeminen datan tuloksista. 
 
 
Helsingin yliopisto on kerännyt 745 ulostenäytettä. Tämän opinnäytetyön tarkoituksena 
oli satunnaistaa ulostenäytteet ensin ja sitten eristää DNA:ta. Eristetyt DNA:n näytteet 
mitattiin NanoDrop-spektrofotometrilaitteella, jotta saatiin selvitettyä näytteiden DNA-pi-
toisuutta. DNA:n eristys tehtiin tunnetun protokollan mukaan. Opinnäytetyön teoreetti-
nen osa sisältää tietoa Parkinsonin taudista ja materiaalien käsittelystä.  
 
 
Tutkimusta varten on kerätty 745 kappaletta ulostenäytteitä, joita näytteet jaettiin satun-
naisesti 23 kappaleen eriin DNA:n eristämistä varten. Kullekin erille lisätiin yksi nolla-
näyte kontaminaatiokontrollia varten, yhteensä 24 näytettä per eristys erä.  
 
NanoDrop-spektrofotometrin tuloksen perusteella alin tulos oli 0,61 ng/L ja korkein tu-
los oli 26,6 g/L. Eristettyjen DNA-näytteiden tutkimukset jatkuvat käyttäen PCR-mo-
nistusta, ja näytteet sekvensoidaan, prosessoidaan bioinformatiikan avulla ja analysoi-
daan tilastollisin menetelmin. 
 
Avainsanat Parkinsonin tauti, DNA, satunnaistaminen, DNA eristäminen, 
NanoDrop spektrifotometri.  
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αSYN  Alpha-Synuclein 
CNS  Central Nervous System 
EtOH  Ethanol 
GI  Gastrointestinal 
IBD  Inflammatory Bowel Disease 
IBS  Irritable Bowel Syndrome 
LPS  Lipopolysaccharide 
NMS  Non-Motor Symptoms 
PD  Parkinson’s Disease  
SNCA  Synuclein Alpha 
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1 Introduction 
 
The study was conducted at the DNA sequencing and genomics laboratory at Institute 
of the Biotechnology University of Helsinki. This work is based on previous studies which 
suggest that there is intestinal dysfunction present in Parkinson’s disease which associ-
ates between certain gut bacteria and the Parkinson’s disease [1]. The project of the 
Parkinson's disease has taken almost three years, which has included planning the pro-
ject, raising fund for the project, collecting the stool samples from Germany, randomizing 
the samples, extracting the DNA from stool samples so that the DNA libraries will build 
by using PCR, sequenced, processing bioinformatically, and analysed with statistical 
methods. 
 
Parkinson’s disease is a neurodegenerative disorder and major cause of losing the do-
paminergic neurons remains unknown. Symptoms will get worse over time [2]. There has 
been evidence that genetic and environmental factors are also connected with Parkin-
son’s disease. The researchers [3] claim that there are different gene mutation in specific 
chromosomal regions. Gene mutations vary in different countries and main risks of de-
veloping Parkinson’s disease in an individual are the presence of another affected family 
member and increasing of the person’s age. The earlier the age of Parkinson's disease 
onset, the higher chance that the genetic factors play a significant role. Environmental 
influences play an important role in the cause of sporadic Parkinson’s disease. Living in 
the countryside has been associated with the agricultural industry, which increases the 
risk of developing Parkinson’s disease. It has been suggested that pesticides and herb-
icides may contribute to causing the increased risk of Parkinson’s disease for those in 
rural areas [3; 4; 5].  
 
The purpose of this study was to randomize the stool samples and extract the DNA. The 
samples were randomized to avoid the batch effects which can bias the result [6] and 
extract the DNA from stool samples. This project is part of the Parkinson's disease study 
to research the connection between of bacteria and Parkinson's disease. 
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2 Parkinson’s Disease (PD) 
 
Parkinson’s disease is a slow chronic and progressive disorder [2] and typically diag-
nosed between ages 50 to 70 [7; 8]. Parkinson’s disease is degenerative disease and 
symptoms will continue and will get worse over time, and the major cause for losing the 
dopaminergic neurons remains unknown [2; 9]. When brain cells start to lose dopamin-
ergic neurons in the substantia nigra, it will start to affect on mood and weaken slowly 
the control of the movements, posture, and balance [10; 11]. Parkinson’s disease has 
different symptoms and primary motor signs are: tremor (hands-, arms-, face- and legs 
shaking), bradykinesia (slowed movement), rigid muscles (muscle stiffness may limit and 
occur in any part of a body, that can cause pain) and postural instability (impaired bal-
ance, condition, loss of automatic movements, speech- and writing changes) [2; 11]. The 
Parkinson’s disease symptoms are described in Figure 1 below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.   Figure on the right show person who has Parkinson's disease and the symptoms 
of Parkinson's disease; tremor, bradykinesia, rigid muscles and postural instability 
[12]. The figure on the left shows where a substantia nigra is located and differ-
ences in the brain structure between healthy person and person who has Parkin-
son's disease [13]. 
 
SYN is naturally occurring protein found in human brain and all nerve cells of the body, 
and in red blood cells, heart, muscle and other cells [14; 15]. -Synuclein is one of first 
genes that has been associated with Parkinson’s disease, and mutation in Synuclein 
alpha (SNCA) causes Parkinson’s disease autosomal dominant forms and is basis risk 
to developing the sporadic Parkinson’s disease [16].  
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The neuronal toxicities -Synuclein cause is unknown in Parkinson’s disease but it 
known that it plays a central role in the pathogenesis of Parkinson’s disease [16]. Figure 
2 shows the Lewy bodies in substantia nigra. Substantia nigra is located in the midbrain 
of Parkinson’s disease patients, and can be seen in figure 1. 
 
 
 
 
 
 
Figure 2.  Lewy Bodies is located in the substantia nigra in midbrain of Parkinson’s disease           
patients [17].  
 
SYN creates precipitates and forms a ball-shaped Lewy bodies in Parkinson’s disease, 
and also develops Parkinson’s disease [3; 5; 18]. 
 
2.1 Risk Factors of Parkinson's Disease 
 
Nowadays researchers have managed to connect gut microbiota in PD, which have sug-
gested intestinal environment can affect the activity of intestinal central nervous system 
(CNS).  Evidence has also been suggesting that the vagus nerve might act as the direct 
canal through which substance from the intestine can pass to the brain. Changes in in-
testinal bacteria population have been associated with Parkinson’s disease, autism, mul-
tiple sclerosis, schizophrenia, depression, anxiety and post-traumatic stress disorder [1].  
 
The human intestine has more than 100 trillion bacteria along with abundant viruses and 
fungi, and the intestinal immune is constantly exposed to microbe antigens that cause 
stimuli that extends inflammatory reaction. Intestinal tissue damage that exposes to sub-
stances that irritate strong immune reactions, can increase the inflammation of the intes-
tinal environment. Also, the introduction of aggressive pathogens, which can turn enteric 
inflammation can induce a numerous of effects that ultimately changes the CNS function. 
Chronic intestinal inflammation disorders may develop eventually Inflammatory Bowel 
4 
 
Disease (IBD) and Irritable Bowel Syndrome (IBS). Also, Lipopolysaccharide (LPS) in-
crease intestinal permeability and are highly immunogenic and activate systemic inflam-
matory responses. Many of these diseases are related to advanced age and intestinal 
inflammation and forms of intestinal permeability increase with aging. Evidence has 
shown that Gastrointestinal (GI) and also Nonmotor Symptoms (NMS) are connected 
with the earliest stage of Parkinson’s disease (PD) [1]. 
 
One of the early stage non-motor symptoms (NMS) of Parkinson’s disease are constipa-
tion, rapid eye movement, sleeping behaviour disorder, hyposmia, anxiety, etc. Consti-
pation is the most common and the second is NMS which is hyposmia in PD. Constipa-
tion is one of the pre-motor symptoms obvious years before CNS degenerations is ap-
parent in diagnosis of PD, and also abnormal enteric αSYN is present before CNS neu-
rodegeneration has advanced satisfactorily to produce motor symptoms [1]. 
 
2.2 Bacteria Connected to Parkinson’s Disease 
 
Researchers have discovered a connection between a few bacteria and Parkinson’s dis-
ease (PD). The bacteria start their development in the guts and the pathology spreads 
to the brain later on. The pathology may be initiated by gut bacteria before diagnosing 
the Parkinson’s disease, the patient suffers from early symptoms such as constipation. 
The bacteria that have been connected to Parkinson’s disease are Prevotellaceae, Lac-
tobacillaceae, Verrucomicrobiaceae, Bradyrhizobiaceae and Clostridiales Incertae Sedis 
IV [19].   
  
The bacteria are located in the intestine and they’re transmitted through metabolism to 
stool. The gut-brain incorporates bidirectional communication between the central nerv-
ous system and the enteric nervous system and endocrine systems. Regulation of im-
mune responses is in the gut, as well as in the brain. The activity of intestine appears to 
be heavily influenced by microbes [1]. 
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2.3 16s rRNA gene sequence 
 
16s rRNA gene sequence is for bacterial identification. Each type of bacteria has different 
sequences, but they are similar to 16s rRNA sequences. The 16s rRNA gene is the most 
used marker gene for economical of large projects and the diversity reference data set 
for bacteria. 16s rRNA gene sequences are used for the study of bacterial taxonomy and 
phylogeny and 16s rRNA gene is generally selected for achieving high taxonomic reso-
lution. 16s rRNA gene sequence informatics is to provide species and genus identifica-
tion for taxa that are infrequently associated with human infectious disease and identifi-
cation for isolations that do not fit slightly recognized biochemical profiles [20; 21].   
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3 Sample Management 
 
It was stated in the previous chapter that bacteria are in a person’s body and are found 
in stools. Researching the DNA of bacteria that are located in stools is more complex for 
the research to reach its desired result. This chapter briefs the theoretical part of the 
management of given samples, and then gives a practical explanation how the sample 
management was implemented for this study. 
 
3.1 The Quantity of Samples Statistically 
 
Important prerequisite is computational tools that are able to quickly and accurately com-
pare large amounts of data produced from complex bacterial communities to identify the 
properties that distinguish them. The extracted DNA samples are sequenced and a met-
agenomic library is created, and the method of metagenomics can be used to search for 
new pathogens or microbes in the intestine [22].  
 
Metagenomics purposes are to comprehend the function and structure of microbial pop-
ulations exclusively through DNA analysis, and statistical method is for detecting the 
differentially large structures between microbial populations.  Each sample is provided 
with count data that represent the relative abundance of specific features with each sam-
ple, for example, 16s rRNA clones a specific taxon. 16s rRNA were explained in previous 
chapter 2.3 [22]. 
 
The statistics are based on probability calculations that study the collection processing 
and statistical analysis of statistical data. The statistics can be used to measure obser-
vations and to deal with data generated by measurements. Statistic can be divided into 
theoretical and applied statistics and plays an important role in analyzing the results [22]. 
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3.2 Sample Storage  
 
Sampling, storing and processing of samples are one of the critical components of DNA-
based microbial community analysis processes of environmental samples. DNA and 
RNA of a stool and the composition of its microbial community can change its form in 
warmer temperature. If stool samples stay at room temperature for 2 weeks, the DNA 
degeneration further increases and nearly all high-molecular weight fragments will dis-
appear. In order to keep the stools highly molecular weight fragments the stool should 
be frozen -20C as soon as a sample of it is taken, so the potential of the sample starting 
to ferment is as minimal as possible. The ideal temperature for sample storage is -80C. 
The storage condition has a large influence on the taxonomic composition of the samples 
bacterial taxa [21; 23; 24].  
 
3.3 Randomization of Samples 
 
The randomizing of the sample right at the beginning prevents the variation of batch 
effect and the result. Randomization is to minimize the so-called batch effects. Batch 
effects causes are unknown technical variables in a study. One the reason that causes 
the batch effects are laboratory conditions, reagent lots and personal differences. This 
becomes a significant problem when batch effects are correlated with an outcome of 
interest and lead to incorrect conclusions [6]. 
 
3.4 Samples Contamination 
 
It is needed to understand all sources that could possible contaminate the samples that 
affect PCR results, for avoiding contamination. Aseptic technique is routine that prevents 
samples, reagents, instruments and other solutions from being contaminated by un-
wanted micro-organisms. There is also related additional issue in the presentation of 
contaminating microbial DNA during sample preparation, and the reason might be DNA 
extraction kit, reagents, and molecular biology grade water. The low microbial biomass 
is easy to contaminate and can affect misleading DNA results [25; 26]. 
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In today’s laboratories, aseptic techniques are critical. The aseptic technique includes 
proper laboratory equipment such as laboratory coat, disposable protective gloves, ster-
ile pipet tips, and tubes [25]. To prevent the sample contaminations, laminar has to be 
cleaned with 70% ethanol (EtOH), and also with DNA away reagent buffer. DNA away 
buffer destroys unwanted DNA and cleans better than 70% ethanol (EtOH). Ethanol 
(EtOH) cleans the laminar, but not the same way as DNA away buffer does. It’s recom-
mended that ethanol and DNA away buffer to be used before using the laminar and after 
using the laminar [25].   
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4 DNA Isolation 
 
DNA extraction of bacteria from stool sample is one of the critical steps. Previous studies 
have demonstrated that many factors can affect the composition of the gut microbiota, 
including human genotype, diet etc. There are many different protocols to extract the 
DNA from bacteria, different sampling, and analytical methods can influence the decided 
microbiome composition. However, most of the protocol follows the same principle to 
extract the DNA: break the cell walls of bacteria and release the DNA, remove inhibitors 
and elute the DNA. Choosing the correct protocol is important to prevent the great impact 
on the purity and amount of DNA [27; 28; 29]. 
 
Stool sample cell lysis can be done in three different ways: enzymatically, chemically or 
mechanically, as described by protocol [27; 29; 30]. Enzymatically and chemically lysis 
methods are careful but also have limited access to all target organisms and selectivity 
for different cell type. Mechanical bead cell lysing, which is used for this study, is the 
most effective method since it not only breaks the cell wall of bacteria but also homoge-
nizes the sample even more.  The effect of beads, lysis, and homogenization gives the 
reagents in the next step an ideal environment for removing PCR inhibitors from the 
sample, although beads provide an effective way of revealing the DNA but lysing the 
sample too much, is considered to be too destructive for chromosomal DNA studies [29].  
 
Stool samples contain many different inhibitors and one of them are complex polysac-
charides and bile salts [31; 32; 33]. Bile salt is conjugated bile acid formed in the liver 
and is one of major bile acid found in humans approximately 0.7 % [34].  
If Bile salt and complex polysaccharides are not removed properly it can inhibit the PCR 
results, depending on cofactors, in the PCR reaction. The PCR is an enzymatic reaction 
and therefore sensitive to inhibitors [35; 36].  
 
The inhibitor removal is done with appropriate bile salt method [30; 37]. Bile salts can be 
inhibited by binding them to molecules such as magnesium hydroxide, cholestyramine, 
sucralfate, meciadanol or aluminium hydroxide [38]. The remaining inhibitors can be re-
moved by a simple washing step since the biding eliminates most inhibitors from the 
samples. For example, silica membrane [37] DNA binding and washing steps reduced 
the amount of PCR inhibitors from 12.5% to 1.1%. The removal of inhibitor is commonly 
done by pelleting the inhibitors through centrifugations or binding the DNA molecules to 
another molecule and by washing surroundings [39]. 
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Stool samples contain normal proteins as well as reagents from extraction kits that inhibit 
PCR reactions. Proteinase K is one of the most commonly used enzymes, which is a 
board-spectrum serine protease digest inhibits the proteins in DNA extraction [40, 41]. It 
has been described in the manual [41] that Proteinase K cleaves peptide bonds at the 
aromatic, carboxyl sides of aliphatic or hydrophobic amino acid. Proteinase K activates 
by urea and dodecylsulfate that is caused primarily by denaturation of the protein sub-
strates. Combination of dodecylsulfate and Proteinase K achieves to protect RNA from 
degradation during isolation of polysomal RNA, in which ribonuclease can’t prevent inhi-
bition without the combination of dodecylsulfate and Proteinase K [41]. Figure 4 shows 
the Proteinase K activity aliphatic reaction.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  An example of Proteinase K chemical polypeptides activity reaction [42]. 
 
 
In the manual [43] it says that recommended working concentration of Proteinase K is 
0.05–1 mg/mL, and that the activity of the enzyme is stimulated by 0.2-1% SDS or 1-4 
M Urea [41]. 
 
The final DNA processing is the washing and elution step. Washing part purifies the DNA 
from most of the remaining PCR inhibitors and pollutant proteins. If a silica column filter 
is used, silicate filter is one of washing steps that can be performed and DNA binds to 
silicate in the presence of strong salts.  This is potentially suitable for negative charge of 
both silica and DNA. The negatively charged ionized salt molecules set between the 
positive charges that form a hydrogen bond. This bond will not break as long as pH stays 
stable and amount of salt stays high. This allows washing further to remove the ethanol 
and salts from DNA. However, it has been established that DNA binds with silica based 
elution, which can be little as 21% of the original amount of DNA [32, 37]. 
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Figure 5 show the silica spin filter, spin column based nuclein acid purification. Nucleic 
acid binds to the solid phase of silica under certain conditions [44]. 
 
 
 
 
 
 
 
 
 
 
Figure 5.   The principle of silica membrane is DNA binding. In the presence of chaotropic 
salt, DNA molecules bind into the hydrolyzed Na+ with hydrogen bond [44].  
 
 
The elution buffer has been designed for storing the samples and the elution of DNA. 
The DNA, bound to the silicate filter, is eluted when the concentration of the binding salt 
is diluted enough. The DNA is eluted through the filter through a centrifuge [30].  
 
For DNA, the 260/280 ratio is used to access purity and a ratio of ~ 2.0 and nucleic acid 
~1.8 is generally accepted as pure. The 260/230 values of pure nucleic acid are often 
higher than the respective 260/280 values and expected values are commonly in the 
range of 2.0 – 2.2 [29, 30, 45]. 
 
4.1 DNA Extraction Kit 
 
The PSP Spin Stool DNA Kit has compounded methods for collection, transportation, 
and storage of stool samples and consequent DNA purification. The PSP kit has been 
designed to be simple to isolate any microorganism’s DNA or host DNA organism. The 
ideal of purified DNA is to trustworthy use in PCR and other any downstream analysis 
[27]. PSP Spin Stool DNA Plus Kit was chosen to extract DNA from the stool sample. 
Researchers in the article [37] had been testing different kind extraction kit, and SPS 
Spin Stool DNA Plus Kit was chosen based on the resulting stool sample collection, 
transportation, and storage [27]. 
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4.2 Controls of DNA Extraction 
 
In the DNA extraction two controls were used. One blank negative PSP kit control and 
one positive ZymoBIOMICS control. The blank control kit makes sure, that the kit rea-
gents are not contaminating the samples, and the kit blank control also is sequenced 
and compared with the samples [30]. During the DNA extraction process, control is pre-
pared at the same time. DNA extracted by protocol [Appendix 1]. In the DNA isolation, 
for example, positive control ZymoBIOMICS can be used. This helps to prevent misread-
ing the analytical results, therefore standardization is critical for minimizing bias and qual-
ity control of entire microbiomics workflows. ZymoBIOMICS microbial community stand-
ard mocks the community of microbial containing of two fungal strains and eight bacterial. 
It includes two tough-to-lyse yeasts (e.g. Saccharomyces cerevisiae), three easy-to-lyse 
Gram-negative bacteria (e.g. Escherichia coli) and five though-to-lyse Gram-positive 
bacteria (e.g. Listeria monocytogenes). The microbial standard is particularly character-
ized and contains irrelevant impurities < 0.01%. ZymoBIOMICS can be used to expose 
error, artifacts, and bias in metagenomics or microbiomics workflows [46]. Zymo-
BIOMICS microbial community standard was prepared at the end of stool samples DNA 
extraction [Appendix 1]. Table 1 shows Microbial community standard mock the microbial 
that are contained in a standard solution.  
 
Table 1. ZymoBIOMICS microbial community standard mocks the community of microbial 
containing of two fungal strains and eight bacterial [46].  
 
Contains bacteria species 
 Pseudomonas aeruginosa  
 Escherichia coli  
 Salmonella enterica  
 Lactobacillus fermentum  
 Enterococcus faecalis  
 Staphylococcus aureus  
 Listeria monocytogenes  
 Bacillus subtilis  
 Saccharomyces cerevisiae  
 Cryptococcus neoformans 
 
 
Blank PSP kit is negative control and ZymoBIOMICS is positive control, which helps to 
prevent misreading the analytical results [30; 46].   
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5 Materials and Methods 
 
Stool samples were from Germany and the total number of samples was 745 pieces. 
They were collected from people who weren’t diagnosed with Parkinson’s disease before 
the day the stool was collected, but they were classified as a risk of Parkinson's disease 
group.  
 
Stool sample microbiomes of 745 risk of developing Parkinson’s disease patients and 34 
kit blank kit controls were DNA extracted, to measure with NanoDrop and later will be 
studied by using PCR, sequenced, processed bioinformatically, and analyzed with sta-
tistical methods [19; 22]. Chapter 2.2 Bacteria connected to Parkinson’s disease, ex-
plained the bacteria. 
 
5.1 Collecting the Samples  
 
Researchers require samples are first collected on container before transferring to sam-
ple tube. The reason why the sample is collected first on the container is to facilitate the 
transfer of stool samples easier to sample tube. There were three types of collector tubes 
from one patient, one for DNA, one for RNA and one for protein analysis. DNA and RNA 
tube were contained the stabilizer solution and protein did not contain in stabilizer solu-
tion [30]. 
 
Stool sample of this study was collected in the tube, which helps to collect, store and 
transport the sample. DNA Stabilizer solution prevents any degeneration of the DNA 
during the transportation, and the prelysis of bacteria fast and effective isolation of high-
quality DNA from the stool sample. DNA stabilizer also preserves the microorganism titer 
[30].  
 
5.2 Randomizations 
 
When the stool samples were arrived at laboratory at department of the University of 
Helsinki, the samples have been stored at -80C freezer, then taken to -20 to randomize 
and prepare batches, and put back to -80 again to minimize the degradation of bulk DNA 
by confining the activity of endogenous nuclease [30]. 
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Samples were randomized by selecting randomly and marked to Excel. Sample boxes 
were marked with DNA extraction and the purification order number. One box contained 
23 samples and one blank control kit. Table 2 shows the Excel table, where samples 
were read with laser barcode scanner. Barcode scanned samples’ barcode and trend ID. 
The barcode was on tube’s label. Information’s helps in interpreting results, if there was 
something in the analysis results and also helps to choose the correct protocol of DNA 
isolations.  
 
Table 2. Box number is extracting order number, barcode, and trend ID number is patient's 
personal number that has been given for DNA extraction and note.    
 
 
 
5.3 DNA Isolation 
 
DNA isolation was done by PSP Spin Stool DNA Plus Kit manual [30]. There were few 
samples that were a solid, or thick, or missing stabilizer in the tube. This kind of samples 
were pipetted by protocol [Appendix 1]. A deviant DNA extraction instruction was for the 
samples that were a missing stabilizer, or solid, or thick samples, the samples were 
weighed 200 mg into a 2,0 ml Safe-Lock-Tube and were added 1,2 ml nuclease-free 
H2O, and vortexed for 1 minute [Appendix 1].   
 
There were some stool samples that thawed quicker than the others, but generally, sam-
ples thaw equally. There were few samples in each box that thaw unequally from the 
norm. There is no significant addition of DNA damage to fragments or variation of bac-
terial species, unless the samples were kept melted for hours or days. The thawing of 
samples usually took about one hour [21; 23; 24]. 
 
Box	Number Barcode Trend	ID Notes Purification	number Trend	ID Tube	Label
DNA_30 DA0237 7028 Tube	is	full	of	stool! 703 7028 DA0237
DNA_30 DA545 7272 704 7272 DA545
DNA_30 DA469 7211 705 7211 DA469
DNA_30 DA643 1227 Tube	full	of	stool,	may	not	have	a	stabilizer 706 1227 DA643
DNA_30 DA0133 7349 707 7349 DA0133
DNA_30 TYD836 1404 May	have	very	littl	DNA	stabilizer 708 1404 TYD836
DNA_30 DA0043 7065 709 7065 DA0043
DNA_30 DA0004 7148 710 7148 DA0004
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ZymoBIOMICS standard were extracted by protocol [46], ZymoBIOMICS standard were 
pipetted 0.75µL into a 2,0 ml Safe-Lock-Tube and were added 1,325 mL DNA stabilizer, 
and continued the same way as protocol [Appendix 1].  
 
5.4 Extracted DNA Measurement with NanoDrop. 
 
Samples were measured with NanoDrop spectrophotometer and the result was saved in 
the folder and the result was printed out. The printed result was attached to the laboratory 
book. The DNA microtube samples were transferred to the storage box and exported to 
a -20°C freezer. The storage box was marked PD DNA Extraction and number order of 
extracted DNA. Figure 7 shows the extracted DNA microtube from the stool sample, and 
on the microtube the sample’s ID label were attached.  
 
 
 
 
 
 
 
 
 
Figure 7.  The collected DNA from stool samples was measured with NanoDrop 
 spectrophotometer. 
  
16 
 
6 Results 
 
745 amount of isolated DNA concentration results were between 0.61ng/L and  
26.6 g/L. The limit of result has been set below 20ng/L because there are a few 
results that were low under 20 ng/L and correlations were either normal, high or low 
result. The purity of extracted DNA values is commonly in the range of 1.8 – 2.0 [30].  
 
Figure 8 shows the all extracted results that were isolated from 745 stool samples, 34 
controls samples. Figure 8 also shows the highest result of 26.6 ng/L, which is sample 
purification number 171 and the lowest result 0.61 ng/L, which is sample purification 
number 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  The result of total 780 samples, including 34 control samples. 
 
All samples average concentration results were 377.80 ng/L and blank control kits sam-
ples purity average were 0.11 ng/L.   
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Figure 9 shows the low result that was lower 20 ng/L of extracted DNA from stool. There 
were a few samples that were under 20 ng/L, but the correlation was three different 
kind of: normal, low and high correlation. 
 
 
Figure 9.  Low concentration result of extracted DNA from stool samples. 
 
Since the results were low, it was wanted to see the purification in clustered column. In 
figure 10 the purification of low samples can be seen. The sample D-93 purification value 
was in 3.34, and sample D-4 and D-263 was the lowest purification. Sample D-4 purifi-
cation value was -1.55, and sample D-263 purification value was 0.18. Most of the sam-
ples were in the wanted purification value ~1.8 – 2.0. Overall, the low results were in the 
limit value. Figure 10 shows the average of standard error results. Average of standard 
error means an average error in statistical science and can be used to measure a confi-
dence interval of a certain probability. 
 
 
Figure 10. Purification of low results that were under 20 ng/L and average of standard error.  
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Figure 11 has been shown the purities of the average and standard error of low samples 
in scatter.  
 
 
Figure 11. Purification of low results that were under 20 ng/L.  
 
 
The low sample concentration results might have affected the missing stabilizer, for ex-
ample sample D-334 had a normal amount of stabilizer solution in the tube but had very 
little sample, and also sample D-522 tube had only half stabilizer solution, which might 
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Appendix 2.  
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DNA mass calculation, the total loss of DNA is calculated by ideal DNA yield minus the 
results of DNA concentration yield: 2 µg – 0.933 µg = 1.065 µg. Total DNA loss was 
1.065 µg. Percent yield is calculated by dividing the actual yield with theoretical yield, 
then multiplying by 100; (0.933 µg/µL / 2 µg) * 100 = 46.7%. The result of percent yield 
is 46.7%. 
 
Blank control kit should be zero, so it does not count purity.  Blank control kit result can 
be seen in appendix 2. 
 
Low results will first drive by PCR (Polymerase Chain Reaction), in which it can be seen 
whether there is need to isolate the new DNA from the stool sample or not. PCR is a 
technique that is used in molecular biology laboratory to amplify a single or few copies 
of a section of DNA across several orders of magnitude, to produce thousands to millions 
of copies of a particular DNA sequence [47]. 
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7 Conclusion 
 
The purpose of the study was to understand the meaning of work, why stool samples 
were randomized and how the DNA extraction is done and what comes next. Chapter 2 
explained the Parkinson’s disease and the batch effects that cause the development of 
this disease.  
 
The results were affected by many factors, for example, the amount of stool in DNA 
stabilizer tube, as some patient put too much stool sample in the tube, and some patients 
put too little stool sample in the DNA stabilizer tube. The result might also be effected 
during DNA extraction protocol, for example during centrifugation. Some of the samples 
required more than one centrifugation because of loosen sample or because sample was 
viscous and did not pass the spin filter. The sample results may have been affected by 
the quality of the stool, as some samples were diarrheal, sticky or loose/solid. It is also 
possible that the results are affected by how the food was digested in the intestines, as 
in some samples was possible to see with bare eyes that the sample food was not di-
gested. It is possible that the patient had digestion problems. The thawing of samples 
began to predict if the sample was sticky or full of diarrhea sample, that was difficult to 
pipet to 2.0 mL safe-lock tube. Pipetting the difficult samples had to do by different pro-
tocol (Appendix 1). Predicting the samples did help to prevent the problem during filtra-
tion. To avoid the mistake during the DNA extraction, it was needed to work carefully and 
work by protocol [30].  
 
Samples ratio of DNA and nuclein acid were measured with NanoDrop spectrophotom-
eter. The approximate ratio of samples was around 2.0, which is accepted as pure, re-
ferring to the chapter 4.3 DNA concentration. 
 
All problems that came during the DNA isolation from stool samples had to be written in 
laboratory book, to be able to go back to them and see what was the problem at that 
point, which will help to understand how these exact results were achieved, and it helps 
to understand why this kind results came. In the laboratory, the PSP spin stool DNA plus 
kit product number, batch- and expiration date number and also micro tube batch infor-
mation had to be written in the book.  
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As standard concentration result was 9.33 ng/L and spectrophotometer purity 260/280 
was 2.17 nm, the result process has been successful since the standard expected yield 
is approximately 2 g/L DNA per preparation. 
 
The stool samples randomizations lasted two weeks in February 2017 and DNA extrac-
tion started after randomization. The DNA of samples were extracted. It took 33 days to 
extract the DNA of samples, one sample box a day. The storage, randomization of sam-
ples, and stool samples were stored in PSP plus kit’s stabilizer buffer as described in 
chapter 3. 
 
The goal was to randomize the 745 pieces of stool samples and to extract the DNA from 
the stool sample. This study will be used to do the building of the DNA libraries by using 
the PCR, sequencing, processing bioinformatically, microbial investigation and analyzing 
with statistical methods. I did my DNA extraction part successfully. 
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Extracted DNA Results 
 
Figure 12. Extraction purification order no. 1-24. Batch no. 1.  
 
 
 
Figure 13. Extraction purification order no. 25-48. Batch no. 2. 
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Figure 14. Extraction purification order no. 49-72. Batch no. 3. 
 
 
 
Figure 15. Extraction purification order no. 73-96. Batch no. 4 
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Figure 16. Extraction purification order no. 97-120. Batch no. 5.  
 
 
 
 
 
 
Figure 17. Extraction purification order no. 121-144. Batch no. 6.   
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Figure 18. Extraction purification order no. 145-168. Batch no. 7. 
 
 
 
 
 
Figure 19. Extraction purification order no. 169-192. Batch no. 8. 
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Figure 20. Extraction purification order no. 193-216. Batch no. 9. 
 
 
 
 
Figure 21. Extraction purification order no. 217-240. Batch no. 10. 
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Figure 22. Extraction purification order no. 241-264. Batch no. 11. 
 
 
 
Figure 23. Extraction purification order no. 265-288. Batch no. 12. 
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Figure 24. Extraction purification order no. 289-312. Batch no. 13. 
 
 
 
 
Figure 25. Extraction purification order no. 313-360. Batch no. 14. 
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Figure 26. Extraction purification order no. 337-360. Batch no. 15. 
 
 
 
 
Figure 27. Extraction purification order no. 361-384. Batch no. 16. 
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Figure 28. Extraction purification order no. 385-408. Batch no. 17. 
 
 
 
 
Figure 29. Extraction purification order no. 409-432. Batch no. 18. 
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Figure 30. Extraction purification order no. 433-480. Batch no. 19.  
 
 
 
 
Figure 31. Extraction purification order no. 457-480. Batch no. 20. 
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Figure 32. Extraction purification order no. 481-504. Batch no. 21. 
 
 
 
 
Figure 33. Extraction purification order no. 505-528. Batch no. 22. 
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Figure 34. Extraction purification order no. 529-552. Batch no. 23. 
 
 
 
 
Figure 35. Extraction purification order no. 553-576. Batch no. 24. 
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Figure 36. Extraction purification order no. 577-600. Batch no. 25. 
 
 
 
 
Figure 37. Extraction purification order no. 601-624. Batch no. 26. 
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Figure 38. Extraction purification order no. 625-648. Batch no. 27. 
 
 
 
 
Figure 39. Extraction purification order no. 649-672. Batch no. 28. 
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Figure 40. Extraction purification order no. 673-696. Batch no. 29.  
 
 
 
 
Figure 41. Extraction purification order no. 697-720. Batch no. 30. 
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Figure 42. Extraction purification order no. 721-744. Batch no. 31. 
 
 
 
 
Figure 43. Extraction purification order no. 745-768. Batch no. 32. 
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Figure 44. Extraction purification order no. 769-780. Batch no. 33. 
 
 
 
Figure 45. All samples purification number 1-782. Batch no. 1-33. 
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Figure 46. Low result under 20 ng/µL. 
 
 
 
 
Figure 47. Low result average of standard error. 
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Figure 48. Low result average of standard error in scatter.  
 
 
 
 
Figure 49. Blank control kit concentration. 
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Figure 50. Blank control kit purification.  
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Table 4. Low sample concentration results. 
 
 
Table 5. Blank concentration kit result. Batches 1-33. DCon2 – Dcon34. 
 
 
Table 6. ZymoBIOMICS Standard result. 
 
